Ronac Mamtani, MD, MSCE
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858
Penn Medicine Provider

About me

  • Section Chief, Genitourinary Cancers, Hematology-Oncology
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: SUNY Stony Brook School of Medicine
  • Residency: NewYork-Presbyterian/Weill Cornell Medical Center
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

201 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

December 2025
patient
December 2025
feel secure in being treated with you
December 2025
dr mamtani is knowledgeable and kind and considerate
December 2025
excellent communication skills . answered all questions

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Mamtani is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Chow RD, Sedhom R, Mamtani R. Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer , JAMA Oncol: 2025

Litt HK, Mamtani R, Chow RD. Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction , Urol Oncol: 2025

Kong AM, Andrean D, Khan S, Choi J, Mamtani R, Parikh R, Jaksa A, Campbell U. Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2 , J Comp Eff Res: 2025

Chow RD, Mamtani R. Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma , Urol Oncol, 43(10): 2025,597

Meng Y, Zhang S, Aout M, Babcock A, Li H, Lai Y, Brand-Wiita S, Notinger S, Bavle A, Mamtani R. Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States , J Med Econ: 2025

Squires P, Cook EE, Song Y, Wang CY, Jiang AX, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R. Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis , J Manag Care Spec Pharm: 2025

Chow RD, Mamtani R. Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma , Clin Genitourin Cancer: 2025

Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R. Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies , JAMA Netw Open, 8(7): 2025,e2520726

Lian Y, Voruganti T, Lu J, Long Q, Mamtani R. Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates , JAMA Netw Open, 8(7): 2025,e2519524

Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R. Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer , J Natl Cancer Inst, 117(6): 2025,1276-1278